Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma

• DOI: 10.1111/cas.15575
• Publication Date: 2022-09-09T18:17:43Z
• Authors: Seila Lorenzo‐Her...; Christian Sordo‐B...; Alejandra Martíne...; Mª. Daniela Corte...; Iván Fernández‐Vega; Mª. Pilar Solís‐H...; Segundo González
• Keywords: Immune checkpoint; Temozolomide; HLA-G

Glioblastoma stands as the most frequent primary brain tumor. Despite multimodal therapy for glioblastoma patients, survival rate is very low, highlighting need novel therapies that improve patient outcomes. Immune checkpoint blockade strategies are achieving promising results in a myriad of tumors and several studies have reported its efficacy at preclinical level. ILT2 immune exerts an inhibitory effect via interaction with classical non-classical HLA class-I molecules. Herein, we report promotes antitumor responses against glioblastoma. In silico immunohistochemical analyses revealed expression ligands HLA-A, -B, -C, -E highly expressed patients Disruption blocking monoclonal antibodies increased natural killer cell-mediated IFN-γ production cytotoxicity glioblastoma, partially reverting immunosuppression linked to this malignancy. addition, co-treatment temozolomide strengthened capacity anti-ILT2-treated cells. Collectively, our establish basis future regarding clinical potential alone or combination regimens